Dragos Ciocan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dragos Ciocan has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Marie Cassard-Doulcier
Université Paris-Saclay, INSERM UMR 996-MI2, Microbiome and Metabolome in Liver Disease: from Susceptibility to Treatment, 91400 Orsay, France
2 shared publications - Wanchao Hu
Université Paris-Saclay, Inserm U996, Inflammation, Microbiome and Immunosurveillance, Orsay, France
1 shared publication
Latest Publications
- Open Access
Pectin in Metabolic Liver Disease
Alterations in the composition of the gut microbiota (dysbiosis) are observed in nutritional liver diseases, including non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) and have been shown to be associated with the severity of both. Editing the composition of the microbiota by fecal microbiota transfer or by application of probiotics or prebiotics/fiber in rodent models and human proof-of-concept trials of NAFLD and ALD have demonstrated its possible contribution to reducing the progression of liver damage. In this review, we address the role of a soluble fiber, pectin, in reducing the development of liver injury in NAFLD and ALD through its impact on gut bacteria.
Open AccessPectin in Metabolic Liver Disease
Alterations in the composition of the gut microbiota (dysbiosis) are observed in nutritional liver diseases, including non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) and have been shown to be associated with the severity of both. Editing the composition of the microbiota by fecal microbiota transfer or by application of probiotics or prebiotics/fiber in rodent models and human proof-of-concept trials of NAFLD and ALD have demonstrated its possible contribution to reducing the progression of liver damage. In this review, we address the role of a soluble fiber, pectin, in reducing the development of liver injury in NAFLD and ALD through its impact on gut bacteria.
- Open Access
- 27 May 2022
- Published by Elsevier in EBioMedicine
- Vol. 81, 104086
In the quest for treating alcohol liver disease
- 27 May 2022
- Published by Elsevier in EBioMedicine
- Vol. 81, 104086
Open AccessIn the quest for treating alcohol liver disease